Fidelity Advisor Biotechnology Fund (FBTTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fidelity Advisor Biotechnology Fund (FBTTX) trades at $41.84 with AI Score 47/100 (Grade C). Fidelity Advisor Biotechnology Fund is a non-diversified fund focused on investing in biotechnology companies. Market cap: $1.90B, Sector: Financial services.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for FBTTX: FBTTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FBTTX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FBTTX: the 1 perspectives are evenly split.
How is this calculated? →Fidelity Advisor Biotechnology Fund (FBTTX) Financial Services Profile
Fidelity Advisor Biotechnology Fund (FBTTX) is a non-diversified fund managing $1.52 billion in assets, specializing in biotechnology companies. The fund invests in both domestic and foreign issuers, utilizing fundamental analysis to identify opportunities within the biotechnology sector, making it a focused investment vehicle for exposure to the biotech industry.
What Is the Investment Thesis for FBTTX?
Fidelity Advisor Biotechnology Fund (FBTTX), with a market capitalization of $1.90B and a beta of 0.90, presents a focused investment opportunity within the biotechnology sector. The fund's non-diversified approach allows for concentrated exposure to companies at the forefront of biotechnological innovation. Growth catalysts include advancements in gene editing technologies, increasing demand for personalized medicine, and regulatory approvals for novel therapies. However, potential risks include clinical trial failures, regulatory hurdles, and competitive pressures within the biotechnology industry. The fund's success hinges on its ability to identify and capitalize on promising biotechnology companies, while effectively managing the inherent risks associated with this dynamic sector. The absence of a dividend yield reflects the fund's focus on capital appreciation rather than income generation.
Based on FMP financials and quantitative analysis
FBTTX Key Highlights
- Market Cap: $1.52B indicates the fund's significant presence in the biotechnology investment landscape.
- Beta: 0.90 suggests the fund's volatility is slightly lower than the overall market, potentially offering a degree of downside protection.
- Non-Diversified: This strategy allows for concentrated investments in high-potential biotechnology companies, potentially leading to higher returns but also increased risk.
- Focus on Biotechnology: The fund's specific focus on biotechnology provides targeted exposure to this innovative and rapidly evolving sector.
- Fundamental Analysis: The fund's investment decisions are based on thorough analysis of financial condition, industry position, and market conditions, aiming for informed investment choices.
Who Are FBTTX's Competitors?
FBTTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FCHKX Fidelity Advisor China Region Fund Class C | $67.35 | -2.41% | $2.72B | 47 |
| FDVIX Fidelity Advisor Diversified International Fund | $32.13 | +0.66% | $1.81B | 44 |
| FHKIX Fidelity China Region Fund | $71.41 | -2.41% | $2.72B | 47 |
| FIUIX Fidelity Utilities Fund | $34.72 | +1.43% | $1.42B | 50 |
| FMSTX Federated Hermes MDT Large Cap Value Fund | $40.25 | +1.39% | $1.86B | 47 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FBTTX's Key Strengths?
- Focused investment strategy in the high-growth biotechnology sector.
- Experienced management team with expertise in biotechnology investing.
- Access to Fidelity's extensive research and resources.
- Non-diversified approach allows for concentrated investments in high-potential companies.
What Are FBTTX's Weaknesses?
- Non-diversified approach can lead to higher volatility and risk.
- High dependence on the success of biotechnology companies.
- Susceptibility to regulatory changes and clinical trial outcomes.
- Potential for high turnover due to the dynamic nature of the biotechnology industry.
What Could Drive FBTTX Stock Higher?
- Advancements in gene editing technologies, driving innovation in the biotechnology sector.
- Increasing demand for personalized medicine, fueling the development of targeted therapies.
- Potential regulatory approvals for novel therapies in late-stage clinical trials.
- Expansion of biotechnology companies into emerging markets with growing healthcare needs.
- Strategic partnerships and collaborations among biotechnology companies, fostering innovation and growth.
What Are the Key Risks for FBTTX?
- Clinical trial failures can significantly impact the value of biotechnology companies.
- Regulatory hurdles and delays can impede the commercialization of new therapies.
- Competitive pressures from other biotechnology companies and investment funds.
- Economic downturns and market volatility can negatively impact the biotechnology sector.
- Patent expirations and generic competition can erode the profitability of biotechnology companies.
What Are the Growth Opportunities for FBTTX?
- Advancements in Gene Editing Technologies: The rapid progress in gene editing technologies, such as CRISPR-Cas9, presents a significant growth opportunity for FBTTX. These technologies hold the potential to revolutionize the treatment of genetic diseases and other medical conditions. The market for gene editing is projected to reach $7.5 billion by 2026, driven by increasing research and development activities and the potential for commercialization of gene-editing therapies. FBTTX can capitalize on this trend by investing in companies at the forefront of gene editing innovation.
- Increasing Demand for Personalized Medicine: The growing trend towards personalized medicine, which tailors medical treatment to individual patients based on their genetic makeup, presents another growth opportunity for FBTTX. Personalized medicine requires sophisticated diagnostic tools and targeted therapies, driving demand for biotechnology products and services. The personalized medicine market is expected to reach $2.4 trillion by 2028, fueled by advancements in genomics and proteomics. FBTTX can benefit from this trend by investing in companies developing personalized medicine solutions.
- Regulatory Approvals for Novel Therapies: The approval of novel therapies by regulatory agencies, such as the FDA, can significantly boost the value of biotechnology companies. These approvals provide a pathway for commercialization and revenue generation. The FDA's accelerated approval pathway encourages the development of therapies for unmet medical needs. FBTTX can capitalize on this by investing in companies with promising drug candidates in late-stage clinical trials, anticipating potential regulatory approvals.
- Expansion into Emerging Markets: The increasing healthcare spending and growing middle class in emerging markets present a significant growth opportunity for FBTTX. These markets offer untapped potential for biotechnology companies to expand their reach and generate new revenue streams. The healthcare market in emerging economies is projected to reach $1.7 trillion by 2027, driven by increasing access to healthcare services and rising disposable incomes. FBTTX can benefit from this trend by investing in companies with a strong presence or expansion plans in emerging markets.
- Strategic Partnerships and Collaborations: Biotechnology companies often form strategic partnerships and collaborations to share resources, expertise, and risks. These partnerships can accelerate drug development, expand market access, and enhance innovation. FBTTX can benefit from these collaborations by investing in companies that actively engage in strategic partnerships, leveraging the synergies created by these alliances.
What Opportunities Does FBTTX Have?
- Advancements in gene editing and personalized medicine.
- Increasing demand for novel therapies and diagnostic tools.
- Expansion into emerging markets with growing healthcare spending.
- Strategic partnerships and collaborations with biotechnology companies.
What Threats Does FBTTX Face?
- Clinical trial failures and regulatory setbacks.
- Competitive pressures from other biotechnology companies and investment funds.
- Economic downturns and market volatility.
- Patent expirations and generic competition.
What Are FBTTX's Competitive Advantages?
- Expertise in Biotechnology: Deep understanding of the biotechnology industry and its dynamics.
- Established Track Record: Proven ability to identify and invest in successful biotechnology companies.
- Access to Information: Access to proprietary research and industry insights.
- Fidelity Brand: Strong brand recognition and reputation within the financial services industry.
What Does FBTTX Do?
Fidelity Advisor Biotechnology Fund (FBTTX) is a specialized investment vehicle within the financial services sector, focusing on the biotechnology industry. The fund's primary objective is to achieve capital appreciation by investing in companies that are principally engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. This includes companies that significantly benefit from scientific and technological advancements in biotechnology. FBTTX invests in both domestic and foreign issuers, providing a global perspective on the biotechnology landscape. The fund employs a fundamental analysis approach, evaluating factors such as an issuer's financial condition, industry position, and prevailing market and economic conditions to make informed investment decisions. As a non-diversified fund, FBTTX concentrates its investments in a smaller number of holdings compared to diversified funds, which can lead to potentially higher volatility but also the possibility of greater returns. The fund's investment strategy is tailored for investors seeking targeted exposure to the biotechnology sector and its growth potential.
What Products and Services Does FBTTX Offer?
- Invests primarily in common stocks of biotechnology companies.
- Focuses on companies engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes.
- Invests in companies that benefit significantly from scientific and technological advances in biotechnology.
- Invests in both domestic and foreign biotechnology issuers.
- Utilizes fundamental analysis to select investments.
- Operates as a non-diversified fund, concentrating its investments.
How Does FBTTX Make Money?
- Generates revenue through capital appreciation of its investments in biotechnology companies.
- Charges management fees based on a percentage of the fund's assets under management.
- Reinvests earnings to maximize long-term growth.
What Industry Does FBTTX Operate In?
Fidelity Advisor Biotechnology Fund operates within the asset management industry, specifically targeting the biotechnology sector. The biotechnology industry is characterized by rapid innovation, high growth potential, and significant regulatory oversight. Market trends include advancements in genomics, personalized medicine, and gene editing technologies. The competitive landscape includes other biotechnology-focused funds and investment firms, each vying for opportunities in this dynamic sector. FBTTX differentiates itself through its focused investment strategy and fundamental analysis approach.
Who Are FBTTX's Key Customers?
- Individual investors seeking exposure to the biotechnology sector.
- Institutional investors looking for specialized investment vehicles.
- Financial advisors seeking to diversify client portfolios with biotechnology investments.
FBTTX Valuation & Market Position
Relative to its peer group, FBTTX's quantitative score of 47/100 is roughly in line with the peer average of 47/100.
FBTTX Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the fund's long-term potential, indicating a positive outlook from management.
- Community sentiment has shifted positively, with discussions highlighting strong performance in biotech sectors, attracting more investors.
- Analysts have noted an increase in biotech innovations, which could lead to significant growth opportunities for the fund.
- Market perception remains bullish as the biotech industry is positioned for recovery and growth post-pandemic, aligning with the fund's focus.
Bear Case
- Some investors express concerns about potential regulatory changes that could impact biotech investments, creating uncertainty.
- Recent discussions reflect skepticism about the fund's ability to outperform its peers amid heightened competition in the biotech space.
- Market volatility has led to cautious sentiment, with some traders worried about the fund's exposure to high-risk biotech startups.
- Recent performance reviews indicate mixed results, leading to doubts about the fund's consistent returns in the current market environment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
FBTTX Latest News
No recent news available for FBTTX.
FBTTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FBTTX.
Price Targets
Wall Street price target analysis for FBTTX.
FBTTX MoonshotScore
What does this score mean?
The MoonshotScore rates FBTTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Common Questions About FBTTX (Financial Services)
What does Fidelity Advisor Biotechnology Fund do?
Fidelity Advisor Biotechnology Fund (FBTTX) is a non-diversified fund that invests primarily in the common stocks of companies engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. The fund aims to capitalize on the growth potential of the biotechnology sector by focusing on companies that are at the forefront of scientific and technological advancements. By concentrating its investments in this specific area, FBTTX offers investors targeted exposure to the biotechnology industry, allowing them to participate in the potential upside while acknowledging the inherent risks associated with this specialized sector.
What are the main risks for FBTTX?
The main risks for Fidelity Advisor Biotechnology Fund (FBTTX) are inherent to the biotechnology sector. Clinical trial failures represent a significant risk, as negative results can dramatically decrease the value of invested companies. Regulatory hurdles and delays in obtaining approvals for new therapies can also impede growth. Competition within the biotechnology industry is intense, with companies constantly vying for market share. Economic downturns and market volatility can negatively impact the sector, and patent expirations can erode profitability. The fund's non-diversified approach amplifies these risks, as a significant portion of its assets are concentrated in a smaller number of holdings.
What are the key factors to evaluate for FBTTX?
Fidelity Advisor Biotechnology Fund (FBTTX) holds an AI score of 47/100 (low). Not financial advice.
How frequently does FBTTX data refresh on this page?
FBTTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FBTTX's recent stock price performance?
Fidelity Advisor Biotechnology Fund (FBTTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused investment strategy in the high-growth biotechnology sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FBTTX overvalued or undervalued right now?
Valuing Fidelity Advisor Biotechnology Fund (FBTTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FBTTX?
Before investing in Fidelity Advisor Biotechnology Fund (FBTTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding FBTTX to a portfolio?
Key strength of Fidelity Advisor Biotechnology Fund (FBTTX): Focused investment strategy in the high-growth biotechnology sector. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for FBTTX, limiting the availability of analyst consensus and detailed financial metrics.
- The biotechnology sector is subject to rapid change and regulatory uncertainty, which can impact investment performance.